Using a cohort of patients whose tumors underwent comprehensive genomic and targeted immune transcriptomic analysis, we characterized the immune gene expression profile of EGFR mutant and Nrf2 altered NSCLC tumor samples. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.